Tetraphase Pharmaceuticals, Inc.
TTPH
TTPH was delisted on the 28th of July, 2020.
1 hedge funds and large institutions have $0 invested in Tetraphase Pharmaceuticals, Inc. in 2020 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 25 closing their positions.
96% less funds holding
Funds holding: 26 → 1 (-25)
100% less capital invested
Capital invested by funds: $5.69M → $0 (-$5.69M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 25
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$3.58M |
| 2 |
Renaissance Technologies
New York
|
-$552K |
| 3 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$524K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$197K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$175K |
TTPH Hedge Fund Activity: Q3 2020 in Review
1 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Tetraphase Pharmaceuticals, Inc. (TTPH) for Q3 2020, worth a combined $0 — down 100% from $5.69M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of TTPH and 0 opened new positions — a net loss of 25 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Armistice Capital, exiting entirely with an estimated $3.58M sold.
- 1 institutional investor held Tetraphase Pharmaceuticals, Inc. (TTPH) as of Q3 2020, down from 26 in Q2 2020.
- Funds reported $0 of Tetraphase Pharmaceuticals, Inc. stock for Q3 2020, down 100% quarter-over-quarter.
- 0 funds opened new Tetraphase Pharmaceuticals, Inc. positions in Q3 2020 and 25 closed out, a net change of -25 holders.
- The largest Tetraphase Pharmaceuticals, Inc. seller in Q3 2020 was Armistice Capital, an estimated $3.58M sold.
Based on aggregated 13F filings for Q3 2020.